Combining agents with complementary mechanisms of action is an increasingly utilized approach for the treatment of cancer (16–18); for example, the use of two HER2-targeted agents with different mechanisms of action has demonstrated robust efficacy in clinical studies of patients with HER2-positive breast cancer (14–18). Here, ERBB2 is linked to breast carcinoma.